Protein-protein interactions among signaling pathways may become new therapeutic targets in liver cancer (Review)
- Authors:
- Xiao Zhang
- Yulan Wang
- Jiayi Wang
- Fenyong Sun
-
Affiliations: Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai 200072, P.R. China - Published online on: November 27, 2015 https://doi.org/10.3892/or.2015.4464
- Pages: 625-638
This article is mentioned in:
Abstract
 |
 |
|
Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Arzumanyan A, Reis HM and Feitelson MA: Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 13:123–135. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S and Mazariegos GV: Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 59:112–131. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lo CM: Liver transplantation in 2012: Transplantation for liver cancer - more with better results. Nat Rev Gastroenterol Hepatol. 10:74–76. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lie PP, Cheng CY and Mruk DD: Signalling pathways regulating the blood-testis barrier. Int J Biochem Cell Biol. 45:621–625. 2013. View Article : Google Scholar : | |
|
Kandori H, Sudo Y and Furutani Y: Protein-protein interaction changes in an archaeal light-signal transduction. J Biomed Biotechnol. 2010(424760)2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty C, Doss CGP, Chen L and Zhu H: Evaluating protein-protein interaction (PPI) networks for diseases pathway, target discovery, and drug-design using 'in silico pharmacology'. Curr Protein Pept Sci. 15:561–571. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Pal I and Mandal M: PI3K and Akt as molecular targets for cancer therapy: Current clinical outcomes. Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E and Lothe RA: Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 1855:104–121. 2015. | |
|
Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sabine VS, Crozier C, Brookes CL, Drake C, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Markopoulos C, Dirix L, et al: Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. J Clin Oncol. 32:2951–2958. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Safdari Y, Khalili M, Ebrahimzadeh MA, Yazdani Y and Farajnia S: Natural inhibitors of PI3K/AKT signaling in breast cancer: Emphasis on newly-discovered molecular mechanisms of action. Pharmacol Res. 93:1–10. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuoka T and Yashiro M: The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancers (Basel). 6:1441–1463. 2014. View Article : Google Scholar | |
|
Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 127:125–137. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 401:82–85. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Y and Wahl LM: Production of matrix metalloproteinase-9 by activated human monocytes involves a phosphatidylinositol-3 kinase/Akt/IKKalpha/NF-kappaB pathway. J Leukoc Biol. 78:259–265. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Vandermoere F, El Yazidi-Belkoura I, Adriaenssens E, Lemoine J and Hondermarck H: The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells. Oncogene. 24:5482–5491. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Tu CC, Cheng LH, Hsu HH, Chen LM, Lin YM, Chen MC, Lee NH, Tsai FJ, Huang CY and Wu WJ: Activation of snail and EMT-like signaling via the IKKαβ/NF-κB pathway in Apicidin-resistant HA22T hepatocellular carcinoma cells. Chin J Physiol. 56:326–333. 2013. View Article : Google Scholar | |
|
Noh JH, Bae HJ, Eun JW, Shen Q, Park SJ, Kim HS, Nam B, Shin WC, Lee EK, Lee K, et al: HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT. Cancer Res. 74:1728–1738. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Cao X, Wang C, Hou L, Nie J, Zhou M and Feng Y: An antitumor peptide from Musca domestica pupae (MATP) induces apoptosis in HepG2 cells through a JNK-mediated and Akt-mediated NF-κB pathway. Anticancer Drugs. 23:827–835. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan Z, Kim D, Shu S, Wu J, Guo J, Xiao L, Kaneko S, Coppola D and Cheng JQ: Phosphoinositide 3-kinase/Akt inhibits MST1-mediated pro-apoptotic signaling through phosphorylation of threonine 120. J Biol Chem. 285:3815–3824. 2010. View Article : Google Scholar | |
|
Wang CY, Tsai AC, Peng CY, Chang YL, Lee KH, Teng CM and Pan SL: Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3β and mTOR signaling pathways. PLoS One. 7:e311952012. View Article : Google Scholar | |
|
Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, Schreiber EM, Day BW and Liu B: APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase. Mol Cell. 32:652–661. 2008. View Article : Google Scholar | |
|
Bauer L, Langer R, Becker K, Hapfelmeier A, Ott K, Novotny A, Höfler H and Keller G: Expression profiling of stem cell-related genes in neoadjuvant-treated gastric cancer: A NOTCH2, GSK3B and β-catenin gene signature predicts survival. PLoS One. 7:e445662012. View Article : Google Scholar | |
|
Hsieh CH, Cheng LH, Hsu HH, Ho TJ, Tu CC, Lin YM, Chen MC, Tsai FJ, Hsieh YL and Huang CY: Apicidin-resistant HA22T hepatocellular carcinoma cells strongly activated the Wnt/β-catenin signaling pathway and MMP-2 expression via the IGF-IR/PI3K/Akt signaling pathway enhancing cell metastatic effect. Biosci Biotechnol Biochem. 77:2397–2404. 2013. View Article : Google Scholar | |
|
Mavila N, James D, Utley S, Cu N, Coblens O, Mak K, Rountree CB, Kahn M and Wang KS: Fibroblast growth factor receptor-mediated activation of AKT-β-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts and hepatic tumor initiating stem cells. PLoS One. 7:e504012012. View Article : Google Scholar | |
|
Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen L, Zhu YH, Li J, Li Y, Ma S, et al: Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar | |
|
Gotoh J, Obata M, Yoshie M, Kasai S and Ogawa K: Cyclin D1 over-expression correlates with beta-catenin activation, but not with H-ras mutations, and phosphorylation of Akt, GSK3 beta and ERK1/2 in mouse hepatic carcinogenesis. Carcinogenesis. 24:435–442. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH, Seo HS and Kim CW: Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. Oncogene. 31:2187–2198. 2012. View Article : Google Scholar | |
|
Niault TS and Baccarini M: Targets of Raf in tumorigenesis. Carcinogenesis. 31:1165–1174. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, et al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet. 44:133–139. 2012. View Article : Google Scholar | |
|
Barthwal MK, Sathyanarayana P, Kundu CN, Rana B, Pradeep A, Sharma C, Woodgett JR and Rana A: Negative regulation of mixed lineage kinase 3 by protein kinase B/AKT leads to cell survival. J Biol Chem. 278:3897–3902. 2003. View Article : Google Scholar | |
|
Kim AH, Khursigara G, Sun X, Franke TF and Chao MV: Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1. Mol Cell Biol. 21:893–901. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmermann S and Moelling K: Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 286:1741–1744. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Kane LP, Mollenauer MN, Xu Z, Turck CW and Weiss A: Akt-dependent phosphorylation specifically regulates Cot induction of NF-kappa B-dependent transcription. Mol Cell Biol. 22:5962–5974. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Park HS, Kim MS, Huh SH, Park J, Chung J, Kang SS and Choi EJ: Akt (protein kinase B) negatively regulates SEK1 by means of protein phosphorylation. J Biol Chem. 277:2573–2578. 2002. View Article : Google Scholar | |
|
Rane MJ, Coxon PY, Powell DW, Webster R, Klein JB, Pierce W, Ping P and McLeish KR: p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J Biol Chem. 276:3517–3523. 2001. View Article : Google Scholar | |
|
Nishitani Y and Matsumoto H: Ethanol rapidly causes activation of JNK associated with ER stress under inhibition of ADH. FEBS Lett. 580:9–14. 2006. View Article : Google Scholar | |
|
Kim JW, Lee JE, Kim MJ, Cho EG, Cho SG and Choi EJ: Glycogen synthase kinase 3 beta is a natural activator of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1). J Biol Chem. 278:13995–14001. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC: HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 3:973–982. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ and Vousden KH: Phosphorylation of HDM2 by Akt. Oncogene. 21:1955–1962. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Z, Ren L, Wei H, Lv J, Che X, Zhu Z, Jia J, Wang L, Lin G, Lu R, et al: Effects of Tyroserleutide on phosphatidylinositol 3′-kinase/AKT pathway in human hepatocellular carcinoma cell. J Drug Target. 22:146–155. 2014. View Article : Google Scholar | |
|
Wang C, Qi R, Li N, Wang Z, An H, Zhang Q, Yu Y and Cao X: Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepato-cellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J Biol Chem. 284:16183–16190. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Song J, Park S, Kim M and Shin I: Down-regulation of Notch-dependent transcription by Akt in vitro. FEBS Lett. 582:1693–1699. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xu L, Zhu Y, Xu J, Wu K, Li J, Xu W, Liu H, Wang S, Yin H, Chen L, et al: Notch1 activation promotes renal cell carcinoma growth via PI3K/Akt signaling. Cancer Sci. 103:1253–1258. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Huntzicker EG, Hötzel K, Choy L, Che L, Ross J, Pau G, Sharma N, Siebel CW, Chen X and French DM: Differential effects of targeting Notch receptors in a mouse model of liver cancer. Hepatology. 61:942–952. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Brana I, Berger R, Golan T, Haluska P, Edenfield J, Fiorica J, Stephenson J, Martin LP, Westin S, Hanjani P, et al: A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours. Br J Cancer. 111:1932–1944. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fielhaber JA, Han YS, Tan J, Xing S, Biggs CM, Joung KB and Kristof AS: Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in alpha4- and protein phosphatase 2A-dependent fashion. J Biol Chem. 284:24341–24353. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yang F, Zhang W, Li D and Zhan Q: Gadd45a suppresses tumor angiogenesis via inhibition of the mTOR/STAT3 protein pathway. J Biol Chem. 288:6552–6560. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sekulić A, Hudson CC, Homme JL, Yin P, Otterness DM, Karnitz LM and Abraham RT: A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res. 60:3504–3513. 2000. | |
|
Dunlop EA and Tee AR: Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. Cell Signal. 21:827–835. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mamane Y, Petroulakis E, LeBacquer O and Sonenberg N: mTOR, translation initiation and cancer. Oncogene. 25:6416–6422. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Q, Lui VW and Yeo W: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Huang Y, Li J and Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 27:255–261. 2010. View Article : Google Scholar | |
|
Nissen NN1, Menon V, Bresee C, Tran TT, Annamalai A, Poordad F, Fair JH, Klein AS, Boland B and Colquhoun SD: Recurrent hepatocellular carcinoma after liver transplant: identifying the high-risk patient. HPB. 13:626–632. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakae J, Kitamura T, Kitamura Y, Biggs WH III, Arden KC and Accili D: The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev Cell. 4:119–129. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hay N: Interplay between FOXO, TOR, and Akt. Biochim Biophys Acta. 1813:1965–1970. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakae J, Kitamura T, Silver DL and Accili D: The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest. 108:1359–1367. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Khor TO, Gul YA, Ithnin H and Seow HF: Positive correlation between overexpression of phospho-BAD with phosphorylated Akt at serine 473 but not threonine 308 in colorectal carcinoma. Cancer Lett. 210:139–150. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Huang CS, Lee YR, Chen CS, Tu SH, Wang YJ, Lee CH, Chen LC, Chang HW, Chang CH, Chih-Ming S, et al: Long-term ethanol exposure causes human liver cancer cells to become resistant to mitomycin C treatment through the inactivation of bad-mediated apoptosis. Mol Carcinog. 49:728–738. 2010.PubMed/NCBI | |
|
Carrano AC and Pagano M: Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression. J Cell Biol. 153:1381–1390. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Lin HK, Wang G, Chen Z, Teruya-Feldstein J, Liu Y, Chan CH, Yang WL, Erdjument-Bromage H, Nakayama KI, Nimer S, et al: Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 11:420–432. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ho C, Wang C, Mattu S, Destefanis G, Ladu S, Delogu S, Armbruster J, Fan L, Lee SA, Jiang L, et al: AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways. Hepatology. 55:833–845. 2012. View Article : Google Scholar : | |
|
Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, et al: International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: Glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 58:782–797. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lin HK, Yeh S, Kang HY and Chang C: Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA. 98:7200–7205. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ma WL, Jeng LB, Lai HC, Liao PY and Chang C: Androgen receptor enhances cell adhesion and decreases cell migration via modulating β1-integrin-AKT signaling in hepatocellular carcinoma cells. Cancer Lett. 351:64–71. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Nie H, Cao Q, Zhu L, Gong Y, Gu J and He Z: Acetylcholine acts on androgen receptor to promote the migration and invasion but inhibit the apoptosis of human hepatocarcinoma. PLoS One. 8:e616782013. View Article : Google Scholar : PubMed/NCBI | |
|
Hong X, Song R, Song H, Zheng T, Wang J, Liang Y, Qi S, Lu Z, Song X, Jiang H, et al: PTEN antagonises Tcl1/hnRNPK-mediated G6PD pre-mRNA splicing which contributes to hepatocarcinogenesis. Gut. 63:1635–1647. 2014. View Article : Google Scholar | |
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology. 52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, et al: A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: Implications for clinical practice. Oncologist. 19:453–458. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kittaka N, Takemasa I, Takeda Y, Marubashi S, Nagano H, Umeshita K, Dono K, Matsubara K, Matsuura N and Monden M: Molecular mapping of human hepatocellular carcinoma provides deeper biological insight from genomic data. Eur J Cancer. 44:885–897. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chan J, Ko FC, Yeung YS, Ng IO and Yam JW: Integrin-linked kinase overexpression and its oncogenic role in promoting tumorigenicity of hepatocellular carcinoma. PLoS One. 6:e169842011. View Article : Google Scholar : PubMed/NCBI | |
|
Peroukides S, Bravou V, Varakis J, Alexopoulos A, Kalofonos H and Papadaki H: ILK overexpression in human hepatocellular carcinoma and liver cirrhosis correlates with activation of Akt. Oncol Rep. 20:1337–1344. 2008.PubMed/NCBI | |
|
Cui Y, Wu W, Zhou Y, Xie Q, Liu T, Jin J and Liu K: HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin. Future Oncol. 9:411–418. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Nam SY, Seo HH, Park HS, An S, Kim JY, Yang KH, Kim CS, Jeong M and Jin YW: Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation. J Biol Chem. 285:31157–31163. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Villagrasa P, Díaz VM, Viñas-Castells R, Peiró S, Del Valle-Pérez B, Dave N, Rodríguez-Asiain A, Casal JI, Lizcano JM, Duñach M, et al: Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene. 31:4022–4033. 2012. View Article : Google Scholar | |
|
Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, et al: MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal. 7:ra712014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao R, Yang HY, Shin J, Phan L, Fang L, Che TF, Su CH, Yeung SC and Lee MH: CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity. Cell Cycle. 12:935–943. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng L, Bai M, Mittal AK, El-Jouni W, Zhou J, Cohen DM, Zhou MI and Cohen HT: Candidate tumor suppressor and pVHL partner Jade-1 binds and inhibits AKT in renal cell carcinoma. Cancer Res. 73:5371–5380. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang WL, Jin G, Li CF, Jeong YS, Moten A, Xu D, Feng Z, Chen W, Cai Z, Darnay B, et al: Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling. Sci Signal. 6:ra32013. View Article : Google Scholar : PubMed/NCBI | |
|
Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM and Gray NS: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 284:8023–8032. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, et al: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 69:6232–6240. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
García-Martínez JM, Moran J, Clarke RG, Gray A, Cosulich SC, Chresta CM and Alessi DR: Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J. 421:29–42. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Monaco AP: The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation. 87:157–163. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Menon KV, Hakeem AR and Heaton ND: Meta-analysis: Recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 37:411–419. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ashworth RE and Wu J: Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol. 6:776–782. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, et al: Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 117:5094–5102. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen L, Shiah HS, Chen CY, Lin YJ, Lin PW, Su WC and Chang JY: Randomized, phase I, and pharmacokinetic (PK) study of RAD001, and mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 27(4587)2009. | |
|
Zhao B, Ma Y, Xu Z, Wang J, Wang F, Wang D, Pan S, Wu Y, Pan H, Xu D, et al: Hydroxytyrosol, a natural molecule from olive oil, suppresses the growth of human hepatocellular carcinoma cells via inactivating AKT and nuclear factor-kappa B pathways. Cancer Lett. 347:79–87. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Omar HA: Arafa el SA, Maghrabi IA and Weng JR: Sensitization of hepatocellular carcinoma cells to Apo2L/TRAIL by a novel Akt/NF-kappaB signalling inhibitor. Basic Clin Pharmacol Toxicol. 114:464–471. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SJ, Hwang JW, Yim H, Yim HJ, Woo SU, Suh SJ, Hyun JJ, Jung SW, Koo JS, Kim JH, et al: Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line. J Gastroenterol Hepatol. 29:1299–1307. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng YH, Yin LH, Grahn TH, Ye AF, Zhao YR and Zhang QY: Anticancer effects of baicalein on hepatocellular carcinoma cells. Phytother Res. 28:1342–1348. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chow AK, Ng L, Sing Li H, Cheng CW, Lam CS, Yau TC, Cheng PN, Fan ST, Poon RT and Pang RW: Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. Curr Cancer Drug Targets. 12:1233–1243. 2012.PubMed/NCBI | |
|
Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K and Zhu XF: Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 5:e11142014. View Article : Google Scholar : PubMed/NCBI | |
|
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Zhang Z, Hill DL, Wang H and Zhang R: Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67:1988–1996. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Li Q, Zhang YH, Tian ZY, Ma HX, Zhao J, Xie SQ and Wang CJ: Antitumor effects and preliminary systemic toxicity of ANISpm in vivo and in vitro. Anticancer Drugs. 24:32–42. 2013. View Article : Google Scholar | |
|
Xie SQ, Zhang YH, Li Q, Xu FH, Miao JW, Zhao J and Wang CJ: 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis. 17:725–734. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tanaka T and Rabbitts TH: Interfering with protein-protein interactions: Potential for cancer therapy. Cell Cycle. 7:1569–1574. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Artavanis-Tsakonas S, Rand MD and Lake RJ: Notch signaling: Cell fate control and signal integration in development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA and Israël A: A novel proteolytic cleavage involved in Notch signaling: The role of the disintegrin-metalloprotease TACE. Mol Cell. 5:207–216. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ayaz F and Osborne BA: Non-canonical notch signaling in cancer and immunity. Front Oncol. 4(345)2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S and Griffin JD: MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet. 26:484–489. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ, et al: Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 143:1660–1669.e7. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, et al: IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell. 45:171–184. 2012. View Article : Google Scholar : | |
|
Nüsslein-Volhard C and Wieschaus E: Mutations affecting segment number and polarity in Drosophila. Nature. 287:795–801. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Pepinsky RB, Zeng C, Wen D, Rayhorn P, Baker DP, Williams KP, Bixler SA, Ambrose CM, Garber EA, Miatkowski K, et al: Identification of a palmitic acid-modified form of human Sonic hedgehog. J Biol Chem. 273:14037–14045. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Porter JA, Young KE and Beachy PA: Cholesterol modification of hedgehog signaling proteins in animal development. Science. 274:255–259. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Marigo V, Davey RA, Zuo Y, Cunningham JM and Tabin CJ: Biochemical evidence that patched is the Hedgehog receptor. Nature. 384:176–179. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, Scott MP, Pennica D, Goddard A, Phillips H, et al: The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 384:129–134. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Taipale J, Cooper MK, Maiti T and Beachy PA: Patched acts catalytically to suppress the activity of Smoothened. Nature. 418:892–897. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS, et al: Dysregulation of the Hedgehog pathway in human hepato-carcinogenesis. Carcinogenesis. 27:748–757. 2006. View Article : Google Scholar | |
|
Patil MA, Zhang J, Ho C, Cheung ST, Fan ST and Chen X: Hedgehog signaling in human hepatocellular carcinoma. Cancer Biol Ther. 5:111–117. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng X, Zeng W, Gai X, Xu Q, Li C, Liang Z, Tuo H and Liu Q: Role of the Hedgehog pathway in hepatocellular carcinoma (Review). Oncol Rep. 30:2020–2026. 2013.PubMed/NCBI | |
|
Koyabu Y, Nakata K, Mizugishi K, Aruga J and Mikoshiba K: Physical and functional interactions between Zic and Gli proteins. J Biol Chem. 276:6889–6892. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Wang YY, Jiang JX, Ma H, Han J, Sun ZY, Liu ZM and Xu ZG: Role of ZIC1 methylation in hepatocellular carcinoma and its clinical significance. Tumour Biol. 35:7429–7433. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Badouel C, Garg A and McNeill H: Herding Hippos: Regulating growth in flies and man. Curr Opin Cell Biol. 21:837–843. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J, et al: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Aragón E, Goerner N, Xi Q, Gomes T, Gao S, Massagué J and Macias MJ: Structural basis for the versatile interactions of Smad7 with regulator WW domains in TGF-β pathways. Structure. 20:1726–1736. 2012. View Article : Google Scholar | |
|
Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G and Blandino G: Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem. 276:15164–15173. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Komuro A, Nagai M, Navin NE and Sudol M: WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem. 278:33334–33341. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yagi R, Chen LF, Shigesada K, Murakami Y and Ito Y: A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 18:2551–2562. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wang W, Huang J and Chen J: Angiomotin-like proteins associate with and negatively regulate YAP1. J Biol Chem. 286:4364–4370. 2011. View Article : Google Scholar : | |
|
Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C and Hong W: Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem. 286:7018–7026. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q and Guan KL: Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 25:51–63. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T, Remue E, Meerschaert K, Vanloo B, Boucherie C, Gfeller D, Bader GD, Sidhu SS, Vandekerckhove J, Gettemans J, et al: Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem J. 432:461–472. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Oka T, Mazack V and Sudol M: Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem. 283:27534–27546. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Wolfe A, Septer S, Edwards G, Zhong X, Abdulkarim AB, Ranganathan S and Apte U: Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 32:38–47. 2012. View Article : Google Scholar | |
|
Vassilev A, Kaneko KJ, Shu H, Zhao Y and DePamphilis ML: TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 15:1229–1241. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao B, Kim J, Ye X, Lai ZC and Guan KL: Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein. Cancer Res. 69:1089–1098. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pobbati AV and Hong W: Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 14:390–398. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Rao VS, Srinivas K, Sujini GN and Kumar GN: Protein-protein interaction detection: Methods and analysis. Int J Proteomics. 2014(147648)2014. View Article : Google Scholar : PubMed/NCBI | |
|
London AS, Patel K, Quinn L and Lemmerer M: Application of coupled affinity-sizing chromatography for the detection of proteolyzed HSA-tagged proteins. Protein Expr Purif. 180:80–84. 2014. | |
|
Tong AH, Evangelista M, Parsons AB, Xu H, Bader GD, Pagé N, Robinson M, Raghibizadeh S, Hogue CW, Bussey H, et al: Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science. 294:2364–2368. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Song Z, Dong C, Wang L, Chen DE, Bi G, Dai M and Liu J: A novel method for purifying bluetongue virus with high purity by co-immunoprecipitation with agarose protein A. Virol J. 7(126)2010. | |
|
Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M and Séraphin B: A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol. 17:1030–1032. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
MacBeath G and Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science. 289:1760–1763. 2000.PubMed/NCBI | |
|
Westwick JK and Michnick SW: Protein-fragment complementation assays (PCA) in small GTPase research and drug discovery. Methods Enzymol. 407:388–401. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Palmer AG III: Enzyme dynamics from NMR spectroscopy. Acc Chem Res. 48:457–465. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Vidal M and Fields S: The yeast two-hybrid assay: Still finding connections after 25 years. Nat Methods. 11:1203–1206. 2014. View Article : Google Scholar | |
|
Güell O, Sagués F and Serrano MA: Essential plasticity and redundancy of metabolism unveiled by synthetic lethality analysis. PLOS Comput Biol. 10:e10036372014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Jin Q, Wang S and Ren R: Modeling and prediction of peptide drift times in ion mobility spectrometry using sequence-based and structure-based approaches. Comput Biol Med. 41:272–277. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Vyas VK, Goel A, Ghate M and Patel P: Ligand and structure-based approaches for the identification of SIRT1 activators. Chem Biol Interact. 228:9–17. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Enright AJ, Iliopoulos I, Kyrpides NC and Ouzounis CA: Protein interaction maps for complete genomes based on gene fusion events. Nature. 402:86–90. 1999.PubMed/NCBI | |
|
Foster HA, Estrada-Girona G, Themis M, Garimberti E, Hill MA, Bridger JM and Anderson RM: Relative proximity of chromosome territories influences chromosome exchange partners in radiation-induced chromosome rearrangements in primary human bronchial epithelial cells. Mutat Res. 756:66–77. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pazos F and Valencia A: In silico two-hybrid system for the selection of physically interacting protein pairs. Proteins. 47:219–227. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Whidden C and Matsen FA IV: Quantifying MCMC exploration of phylogenetic tree space. Syst Biol. 64:472–491. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Altman J, Hédl R, Szabó P, Mazůrek P, Riedl V, Müllerová J, Kopecký M and Doležal J: Tree-rings mirror management legacy: Dramatic response of standard oaks to past coppicing in Central Europe. PLoS One. 8:e557702013. View Article : Google Scholar : PubMed/NCBI | |
|
Gene Ontology, C; Gene and Ontology Consortium: Gene Ontology Consortium: Going forward. Nucleic Acids Res. 43(D1): D1049–D1056. 2015. View Article : Google Scholar | |
|
Xenarios I, Salwínski L, Duan XJ, Higney P, Kim SM and Eisenberg D: DIP, the Database of Interacting Proteins: A research tool for studying cellular networks of protein interactions. Nucleic Acids Res. 30:303–305. 2002. View Article : Google Scholar : | |
|
Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, Boucher L, Heinicke S, Chen D, Stark C, Breitkreutz A, Kolas N, O'Donnell L, et al: The BioGRID interaction database: 2015 update. Nucleic Acids Res. 43(D1): D470–D478. 2015. View Article : Google Scholar | |
|
Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S and Wu J: PINA v2.0: Mining interactome modules. Nucleic Acids Res. 40(D1): D862–D865. 2012. View Article : Google Scholar : | |
|
Patil A, Nakai K and Nakamura H: HitPredict: A database of quality assessed protein-protein interactions in nine species. Nucleic Acids Res. 39(Database): D744–D749. 2011. View Article : Google Scholar | |
|
Hermjakob H, Montecchi-Palazzi L, Lewington C, Mudali S, Kerrien S, Orchard S, Vingron M, Roechert B, Roepstorff P, Valencia A, et al: IntAct: An open source molecular interaction database. Nucleic Acids Res. 32:D452–D455. 2004. View Article : Google Scholar : | |
|
Prieto C and De Las Rivas J: APID: Agile Protein Interaction DataAnalyzer. Nucleic Acids Res. 34(Web Server): W298–W302. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E, et al: MINT, the molecular interaction database: 2012 update. Nucleic Acids Res. 40(D1): D857–D861. 2012. View Article : Google Scholar : | |
|
Song JJ and Lee YJ: Dissociation of Akt1 from its negative regulator JIP1 is mediated through the ASK1-MEK-JNK signal transduction pathway during metabolic oxidative stress: A negative feedback loop. J Cell Biol. 170:61–72. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kang D, Sun BK, Kim JH and Song JJ: TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex. Cell Signal. 25:372–379. 2013. View Article : Google Scholar | |
|
Deregibus MC, Cantaluppi V, Doublier S, Brizzi MF, Deambrosis I, Albini A and Camussi G: HIV-1-Tat protein activates phosphatidylinositol 3-kinase/AKT-dependent survival pathways in Kaposi's sarcoma cells. J Biol Chem. 277:25195–25202. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Polzien L, Baljuls A, Rennefahrt UE, Fischer A, Schmitz W, Zahedi RP, Sickmann A, Metz R, Albert S, Benz R, et al: Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: Pore-forming activity of BAD is regulated by phosphorylation. J Biol Chem. 284:28004–28020. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN and Yang Q: Negative regulation of AKT activation by BRCA1. Cancer Res. 68:10040–10044. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang T, Jia Y, Sherris D, Li S, Wang H, Lu D and Yang Q: Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene. 30:2443–2450. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Du K and Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 273:32377–32379. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki H, Daitoku H, Hatta M, Aoyama H, Yoshimochi K and Fukamizu A: Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc Natl Acad Sci USA. 102:11278–11283. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Brent MM, Anand R and Marmorstein R: Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification. Structure. 16:1407–1416. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Biggs WH III, Meisenhelder J, Hunter T, Cavenee WK and Arden KC: Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA. 96:7421–7426. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Zhao R, Yang HY and Lee MH: Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity. Oncogene. 24:1924–1935. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Matsuzaki H, Ichino A, Hayashi T, Yamamoto T and Kikkawa U: Regulation of intracellular localization and transcriptional activity of FOXO4 by protein kinase B through phosphorylation at the motif sites conserved among the FOXO family. J Biochem. 138:485–491. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, et al: Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 30:457–470. 2011. View Article : Google Scholar | |
|
Drendall CI, Pham QH and Dietze EC: Purification and characterization of recombinant CH3 domain fragment of the CREB-binding protein. Protein Expr Purif. 70:196–205. 2010. View Article : Google Scholar : | |
|
Connor MK, Azmi PB, Subramaniam V, Li H and Seth A: Molecular characterization of ring finger protein 11. Mol Cancer Res. 3:453–461. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, Hur L, Grabiner BC, Lin X, Darnay BG, et al: The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 325:1134–1138. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD and Boswell HS: Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. Exp Hematol. 34:1360–1376. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kim CK, Lee SB, Nguyen TL, Lee KH, Um SH, Kim J and Ahn JY: Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. Exp Cell Res. 318:136–143. 2012. View Article : Google Scholar | |
|
Deep G, Oberlies NH, Kroll DJ and Agarwal R: Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway. Oncogene. 27:3986–3998. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Milne D, Kampanis P, Nicol S, Dias S, Campbell DG, Fuller-Pace F and Meek D: A novel site of AKT-mediated phosphorylation in the human MDM2 oncoprotein. FEBS Lett. 577:270–276. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, Lowry C, Newton AC, Mao Y, Miao RQ, et al: The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 27:1932–1943. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Oh WJ, Wu CC, Kim SJ, Facchinetti V, Julien LA, Finlan M, Roux PP, Su B and Jacinto E: mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide. EMBO J. 29:3939–3951. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Glidden EJ, Gray LG, Vemuru S, Li D, Harris TE and Mayo MW: Multiple site acetylation of Rictor stimulates mammalian target of rapamycin complex 2 (mTORC2)-dependent phosphorylation of Akt protein. J Biol Chem. 287:581–588. 2012. View Article : Google Scholar : | |
|
Fan CD, Lum MA, Xu C, Black JD and Wang X: Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem. 288:1674–1684. 2013. View Article : Google Scholar : | |
|
Persaud A, Alberts P, Amsen EM, Xiong X, Wasmuth J, Saadon Z, Fladd C, Parkinson J and Rotin D: Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol Syst Biol. 5(333)2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mistafa O, Ghalali A, Kadekar S, Högberg J and Stenius U: Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem. 285:27900–27910. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nguyen H, Thomas CE, Iversen ES Jr, Marsillac S, et al: Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal. 5:rs62012. View Article : Google Scholar : PubMed/NCBI | |
|
Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 22:159–168. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ikenoue T, Inoki K, Yang Q, Zhou X and Guan KL: Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 27:1919–1931. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CH, Shaikenov T, Peterson TR, Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK and Sarbassov D: ER stress inhibits mTORC2 and Akt signaling through GSK-3β-mediated phosphorylation of rictor. Sci Signal. 4:ra102011. View Article : Google Scholar | |
|
Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M and Gupta MP: The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 4:ra462011. View Article : Google Scholar : PubMed/NCBI | |
|
Gao D, Inuzuka H, Tseng A, Chin RY, Toker A and Wei W: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 11:397–408. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T and Kolch W: Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 70:1195–1203. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kim D, Shu S, Coppola MD, Kaneko S, Yuan ZQ and Cheng JQ: Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS One. 5:e96162010. View Article : Google Scholar : PubMed/NCBI |
